TGF-α/EGFR chemotaxis drives lymphatic metastasis and early immune suppression, revealing a repositionable therapeutic target in breast cancer

preprint OA: closed CC-BY-4.0
📄 Open PDF Full text JSON View at publisher

Abstract

Abstract The epidermal growth factor receptor (EGFR) is a well-established oncogenic driver in multiple epithelial cancers, yet its role in breast cancer remains elusive, with EGFR-targeted therapies showing limited clinical efficacy. Here, we demonstrate that EGFR promotes selective lymphatic dissemination in triple-negative breast cancer through a chemotactic mechanism involving the EGFR ligand TGF-α. Using murine and human breast cancer models, we identify lymphatic endothelial cells (LECs) as a tumor-associated source of TGF-α, particularly upon stimulation with TGF-β1, a cytokine commonly overexpressed in breast tumors. We show that TGF-α–EGFR interactions elicit directional migration via STAT3 signaling, whereas the co-secreted ligand CTGF, enriched in blood endothelium, suppresses migration. Pharmacologic blockade of TGF-α with Fepixnebart, a first-in-class ligand-neutralizing antibody targeting TGF-α and previously not tested in oncologic indications, significantly inhibited early lymph metastasis of EGFR⁺ tumor cells. Furthermore, EGFR overexpression accelerated immune suppression in tumor-draining lymph nodes, suggesting a link between early dissemination and pre-metastatic niche formation. Together, these findings reveal an unexpected, growth-independent function for EGFR in lymph metastasis and propose a rationale for repositioning EGFR-targeted therapies toward targeting early metastatic spread and immunosuppression in breast cancer.
Full text 14,542 characters · extracted from preprint-html · click to expand
TGF-α/EGFR chemotaxis drives lymphatic metastasis and early immune suppression, revealing a repositionable therapeutic target in breast cancer | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article TGF-α/EGFR chemotaxis drives lymphatic metastasis and early immune suppression, revealing a repositionable therapeutic target in breast cancer Wenyang Shi, Yueyun Pan, Bhavik Rathod, Yuhan Wang, Zhi Wang, and 9 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-7487369/v1 This work is licensed under a CC BY 4.0 License Status: Posted Version 1 posted You are reading this latest preprint version Abstract The epidermal growth factor receptor (EGFR) is a well-established oncogenic driver in multiple epithelial cancers, yet its role in breast cancer remains elusive, with EGFR-targeted therapies showing limited clinical efficacy. Here, we demonstrate that EGFR promotes selective lymphatic dissemination in triple-negative breast cancer through a chemotactic mechanism involving the EGFR ligand TGF-α. Using murine and human breast cancer models, we identify lymphatic endothelial cells (LECs) as a tumor-associated source of TGF-α, particularly upon stimulation with TGF-β1, a cytokine commonly overexpressed in breast tumors. We show that TGF-α–EGFR interactions elicit directional migration via STAT3 signaling, whereas the co-secreted ligand CTGF, enriched in blood endothelium, suppresses migration. Pharmacologic blockade of TGF-α with Fepixnebart, a first-in-class ligand-neutralizing antibody targeting TGF-α and previously not tested in oncologic indications, significantly inhibited early lymph metastasis of EGFR⁺ tumor cells. Furthermore, EGFR overexpression accelerated immune suppression in tumor-draining lymph nodes, suggesting a link between early dissemination and pre-metastatic niche formation. Together, these findings reveal an unexpected, growth-independent function for EGFR in lymph metastasis and propose a rationale for repositioning EGFR-targeted therapies toward targeting early metastatic spread and immunosuppression in breast cancer. Breast cancer EGFR lymph metastasis TGF-α Fepixnebart Full Text Additional Declarations No competing interests reported. Supplementary Files MSshietalSUPPLFIGS.pdf MSshietalSUPPLFIGSWBs.pdf Cite Share Download PDF Status: Posted Version 1 posted You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-7487369","acceptedTermsAndConditions":true,"allowDirectSubmit":true,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":508006056,"identity":"c8e93e59-cb10-4669-be8c-2a8cdb7d5363","order_by":0,"name":"Wenyang Shi","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Wenyang","middleName":"","lastName":"Shi","suffix":""},{"id":508006057,"identity":"0a2c09b4-2e46-4e03-b54d-b9e37de5b7f2","order_by":1,"name":"Yueyun Pan","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Yueyun","middleName":"","lastName":"Pan","suffix":""},{"id":508006058,"identity":"b2a2de1d-e395-4b9f-881b-b644c59d3ae6","order_by":2,"name":"Bhavik Rathod","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Bhavik","middleName":"","lastName":"Rathod","suffix":""},{"id":508006059,"identity":"f8c61612-1256-4793-b8e7-a83a72af3fe3","order_by":3,"name":"Yuhan Wang","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Yuhan","middleName":"","lastName":"Wang","suffix":""},{"id":508006060,"identity":"81924648-26fb-44fa-b5db-4d65646622ee","order_by":4,"name":"Zhi Wang","email":"","orcid":"","institution":"Uppsala University","correspondingAuthor":false,"prefix":"","firstName":"Zhi","middleName":"","lastName":"Wang","suffix":""},{"id":508006061,"identity":"23b39f9c-801c-4d65-96bf-d2a96c7bdcff","order_by":5,"name":"Jianyu Shen","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Jianyu","middleName":"","lastName":"Shen","suffix":""},{"id":508006062,"identity":"36edc948-692d-4379-ad07-4f3041fac2cc","order_by":6,"name":"Francesca Gatto","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Francesca","middleName":"","lastName":"Gatto","suffix":""},{"id":508006064,"identity":"e1abc1ce-8d55-4afa-9009-0e72b28ea71d","order_by":7,"name":"Mingzhi Liu","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Mingzhi","middleName":"","lastName":"Liu","suffix":""},{"id":508006066,"identity":"6f4c3977-e2ff-4a5f-a038-137e643c85db","order_by":8,"name":"Margareta Wilhelm","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Margareta","middleName":"","lastName":"Wilhelm","suffix":""},{"id":508006068,"identity":"37551846-31fc-4d72-a2a7-e7db27cda76e","order_by":9,"name":"Thomas Helleday","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Thomas","middleName":"","lastName":"Helleday","suffix":""},{"id":508006069,"identity":"e0dee03b-8dcc-4433-b1e3-15d9d6784fbf","order_by":10,"name":"Maria Ulvmar","email":"","orcid":"","institution":"Uppsala University","correspondingAuthor":false,"prefix":"","firstName":"Maria","middleName":"","lastName":"Ulvmar","suffix":""},{"id":508006070,"identity":"cd7da8d4-88aa-425b-a019-eaeff105b430","order_by":11,"name":"Sara Windahl","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Sara","middleName":"","lastName":"Windahl","suffix":""},{"id":508006071,"identity":"0bd01163-d6ef-4d09-a37d-f0e549150db0","order_by":12,"name":"Mikael Karlsson","email":"","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":false,"prefix":"","firstName":"Mikael","middleName":"","lastName":"Karlsson","suffix":""},{"id":508006072,"identity":"262c69b5-1131-41a6-b74b-759c53806cac","order_by":13,"name":"Jonas Fuxe","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAAwklEQVRIiWNgGAWjYBACxgYwJQfEzIcZEkjQYgzEbMnEaYECkBYeY+LUMrf3Hvz4g8EgccPxns8GDxjq5Ag7rOdcsjQPUMvMnrObExIYDhO2inFGjoE0A8OfxH6J3M0HEhgOJDYQocX4J8hhbfJvHgO11NUTo8VMAuSwfgkeZqDDmBOI8MsZM2seAwPjmT1pxgYJBocNCdpi2N5jfPNHhYHshuOHH0v+qKiTJ2gLxFADGNcAp0IEIGzoKBgFo2AUjAIA6Jo4HiUSSHIAAAAASUVORK5CYII=","orcid":"","institution":"Karolinska Institutet","correspondingAuthor":true,"prefix":"","firstName":"Jonas","middleName":"","lastName":"Fuxe","suffix":""}],"badges":[],"createdAt":"2025-08-29 09:53:23","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-7487369/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-7487369/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":90567745,"identity":"5f24e905-2447-4ffb-a90c-766ba53b5cbf","added_by":"auto","created_at":"2025-09-04 07:47:05","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":804718,"visible":true,"origin":"","legend":"","description":"","filename":"MSShietalTEXTFIGS.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7487369/v1_covered_9ff1688c-8446-4e3e-97af-e0ec078db1a3.pdf"},{"id":90504652,"identity":"7bcb7c54-0146-431b-8f17-6de528538dc9","added_by":"auto","created_at":"2025-09-03 12:23:41","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"supplement","size":4335160,"visible":true,"origin":"","legend":"","description":"","filename":"MSshietalSUPPLFIGS.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7487369/v1/a7fe27c791759793d2e50a57.pdf"},{"id":90504051,"identity":"caacb1cf-50d4-441a-9e94-150095819a4d","added_by":"auto","created_at":"2025-09-03 12:15:41","extension":"pdf","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":1027051,"visible":true,"origin":"","legend":"","description":"","filename":"MSshietalSUPPLFIGSWBs.pdf","url":"https://assets-eu.researchsquare.com/files/rs-7487369/v1/9d9dc6c5d0bcf0b0d56fa039.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"TGF-α/EGFR chemotaxis drives lymphatic metastasis and early immune suppression, revealing a repositionable therapeutic target in breast cancer","fulltext":[],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":false,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":true,"hideJournal":true,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":true,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":true,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true},"keywords":"Breast cancer, EGFR, lymph metastasis, TGF-α, Fepixnebart","lastPublishedDoi":"10.21203/rs.3.rs-7487369/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-7487369/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eThe epidermal growth factor receptor (EGFR) is a well-established oncogenic driver in multiple epithelial cancers, yet its role in breast cancer remains elusive, with EGFR-targeted therapies showing limited clinical efficacy. Here, we demonstrate that EGFR promotes selective lymphatic dissemination in triple-negative breast cancer through a chemotactic mechanism involving the EGFR ligand TGF-α. Using murine and human breast cancer models, we identify lymphatic endothelial cells (LECs) as a tumor-associated source of TGF-α, particularly upon stimulation with TGF-β1, a cytokine commonly overexpressed in breast tumors. We show that TGF-α\u0026ndash;EGFR interactions elicit directional migration via STAT3 signaling, whereas the co-secreted ligand CTGF, enriched in blood endothelium, suppresses migration. Pharmacologic blockade of TGF-α with Fepixnebart, a first-in-class ligand-neutralizing antibody targeting TGF-α and previously not tested in oncologic indications, significantly inhibited early lymph metastasis of EGFR⁺ tumor cells. Furthermore, EGFR overexpression accelerated immune suppression in tumor-draining lymph nodes, suggesting a link between early dissemination and pre-metastatic niche formation. Together, these findings reveal an unexpected, growth-independent function for EGFR in lymph metastasis and propose a rationale for repositioning EGFR-targeted therapies toward targeting early metastatic spread and immunosuppression in breast cancer.\u003c/p\u003e","manuscriptTitle":"TGF-α/EGFR chemotaxis drives lymphatic metastasis and early immune suppression, revealing a repositionable therapeutic target in breast cancer","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2025-09-03 12:15:36","doi":"10.21203/rs.3.rs-7487369/v1","editorialEvents":[{"type":"communityComments","content":0}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"researchsquare","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":true,"externalIdentity":"","sideBox":"","snPcode":"","submissionUrl":"/submission","title":"Research Square","twitterHandle":"researchsquare","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"","reportingPortfolio":"","inReviewEnabled":false,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"3280b8ea-aba9-4565-8f28-ebab1e13c7da","owner":[],"postedDate":"September 3rd, 2025","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"posted","subjectAreas":[],"tags":[],"updatedAt":"2025-09-04T07:38:51+00:00","versionOfRecord":[],"versionCreatedAt":"2025-09-03 12:15:36","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-7487369","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-7487369","identity":"rs-7487369","version":["v1"]},"buildId":"8U1c8b4HqxoKbykW_rLl7","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: preprint-html

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-06-06T02:00:05.402940+00:00
License: CC-BY-4.0